INTRODUCTION {#s1}
============

Proteoglycans (PGs) are complex macromolecules composed of a core protein and covalently linked polysaccharide chain(s) which play a critical role in cell-cell and cell-matrix interactions. Disruptions of such interactions might affect B cell interaction with surrounding stroma and may thus perturb the cell phenotypes. The possible role of PGs has so far been largely neglected, both during B-cell differentiation and as a factor in EBV-driven lymphomagenesis \[[@R1], [@R2]\].

It has been shown that PGs and their polysaccharide chains (especially heparan sulfates, HS) play an important role in the immune system participating in leukocyte development and migration, immune activation and inflammatory processes as well as in lymphoma development \[[@R3]\]. Tightly regulated HSPGs expression is a requirement for normal B cell maturation, differentiation and function \[[@R4]\] and the conformation of their HS polysaccharide chains is crucial for recruitment of factors that control plasma cell survival \[[@R5]\]. Correct modification of HS by the HS-modifying enzyme glucuronyl C5-epimerase (Glce), which controls HS chain flexibility, is required for proper lymphoid organ development \[[@R6]\]. Exogenous extracellular heparin inhibits BL cell proliferation while internalized heparin promotes it \[[@R7]\], and treatment of B cells with chondroitin sulphate (CS) activates B cells *in vitro* and induces HSPG CD138/syndecan-1 expression, affecting humoral immune response in mice \[[@R8]\].

Although a functional role of proteoglycans in normal B cell physiology and malignant transformation has been documented, controversies remain on PGs expression patterns in different immune cell types.

The CSPG serglycin is identified as a dominant PG in immune cells with an important functional role in immune system processes and inflammation \[[@R9], [@R10]\]. It is a major CSPG expressed by primary lymphocytes, although lymphoid cell lines express both serglycin and one or more types of cell surface proteoglycans of the syndecan/glypican families, displaying a presence of HS at their cell surface \[[@R11]\]. Syndecan-1 (CD138), a transmembrane HSPG, functions as a matrix receptor by binding cells to interstitial collagens, fibronectin, and thrombospondin. In bone marrow, syndecan is expressed only on precursor B cells. Syndecan 1) is lost immediately before maturation and release of B lymphocytes into the circulation, 2) is absent on circulating and peripheral B lymphocytes, and 3) is re-expressed upon their differentiation into immobilized plasma cells. Thus, syndecan mediates B cell stage-specific adhesion \[[@R12], [@R13]\]. Syndecan is expressed in chronic lymphocytic leukaemia B-CLL, both in tissue environment and in circulation \[[@R14], [@R15]\]. Syndecan expression is not detected in normal and malignant T cells \[[@R16]\]. Polysaccharide chains of syndecan-1 may contribute to homotypic adhesion and take part in the regulation of cell proliferation and active cell death in HT58 lymphoma cells \[[@R17]\].

Besides a functional role of PGs in the immune system, they are shown to be involved in virus-host cell interactions \[[@R18]--[@R20]\], including enterovirus 71 (EV71) \[[@R21]\], human immunodeficiency virus (HIV-1) \[[@R22]\], foamy virus (FV) \[[@R23]\], herpes virus 8 (HHV-8) \[[@R24]\], herpes simplex virus type-1 (HSV-1) \[[@R25], [@R26]\]. Some PGs have also been studied in EBV-associated cancers and premalignant conditions: chondroitinsulfate proteoglycan CD44 is detected in EBV-associated NPC \[[@R27]--[@R29]\] and EBV-related gastric carcinoma \[[@R30]\]; syndecan-1 (CD138) has been suggested to play a role in EBV-related PTLD \[[@R31]\].

PGs might also be involved in EBV infection of human lymphoid cells and affect EBV-host cell interaction and even lymphoma development.

Most investigated is CD44, the receptor for hyaluronic acid (HA), implicated in enhanced lymphoid tumor growth and dissemination. Although no changes in CD44 expression levels are shown during B cell activation by experimental EBV infection \[[@R32]\], it seems to be differentially associated with EBV-transformed lymphoblastoid cell lines and Burkitt\'s lymphoma cells biology. EBV-transformed LCLs abundantly express CD44, which is absent or minimally expressed in EBV-positive or EBV-negative BL cell lines \[[@R33]\]. However, the treatment EBV+ BL cells with B cell mitogen phorbol 12-myristate 13-acetate (PMA) or cytokine IL-4 enhances expression of an isoform H of CD44 and induces strong HA recognition in the cells. The ability to recognize HA was not observed in B-LCL cells stimulated with either PMA or IL-4 suggesting selective inactivation of molecular pathways that regulate CD44 expression and CD44-mediated HA binding in LCL cells \[[@R34]\]. Introduction of EBV latent membrane protein I (LMP1) gene into BL cells induces expression of CD44 on the cell surface suggesting that expression of LMP1 may regulate expression of CD44 and play a role in the behavior of EBV-based lymphomas \[[@R35]\].

An involvement of serglycin and syndecan-1/CD138 in EBV-host interactions has also been reported. Experimental infection of terminally differentiated tumor derived B cells (multiple myeloma, MM) with EBV virus *in vitro* results in down-regulation of syndecan-1/CD138 expression \[[@R12]\]. EBV infection of BL cells *in vitro* significantly up-regulates expression of nine genes including those encoding serglycin core protein and CD44 \[[@R36]\]. The data suggest a possible involvement of PGs in EBV-driven lymphangiogenesis, but the matter was not thoroughly investigated. The full spectrum of proteoglycans involved and possible molecular mechanisms of their involvement remain unclear.

In this study, we investigate the expression of proteoglycans, the metabolic system for HS chains biosynthesis, modification and degradation, and some key extracellular matrix components (collagen 1A1, fibronectin, laminin) in EBV infected B cell lines.

RESULTS {#s2}
=======

PG expression in human lymphoid cells is associated with EBV infection {#s2_1}
----------------------------------------------------------------------

A panel of EBV+ Burkitt\'s lymphoma cell lines with different EBV latency stages (type III: Raji, Daudi, Mutu III cl 99; type I: Rael, Akata, Mutu I cl148) and lymphoblastoid B cell lines generated by EBV transformation of normal human B cells *in vitro* (CBMI-Ral-STO, CBC-JK2-STO, Nad20) were used (Table [1](#T1){ref-type="table"}). Altogether they represent a unique experimental cell line model to investigate molecular mechanisms of EBV effects on malignant transformation of human B cells \[[@R37]\].

###### Cell lines characterization

  Cell line        EBV latency   Malignant   Clumps   Virus source   *In vitro* transfection   Cell source
  ---------------- ------------- ----------- -------- -------------- ------------------------- ----------------------------
  CBM1-Ral-STO     III           −           +++      Rael           \+                        Human B-cell (cord blood)
  CBC-JK2-STO      III           −           +++      Jijoye         \+                        Human B-cell (cord blood)
  Nad20            III           −           +++      B95--8         \+                        Human B-cell (Adult Blood)
  Rael             I             \+          −        Tumor          −                         Burkitt Lymphoma
  Akata            I             \+          −        Tumor          −                         Burkitt Lymphoma
  Mutu I cl.148    I             \+          −        Tumor          −                         Burkitt Lymphoma
  Mutu III cl.99   III           \+          ++       Tumor          −                         Burkitt Lymphoma
  Raji             II-III        \+          \+       Tumor          −                         Burkitt Lymphoma
  Daudi            II-III        \+          \+       Tumor          −                         Burkitt Lymphoma

Primary B-cells and EBV- lymphoma cell line (DG75) were used as a control. Expression of main PGs (syndecan-1, glypican-1, perlecan, versican, brevican, aggrecan, NG2, serglycin, decorin, biglycan, lumican and facultative chondroitinsulfate proteoglycan CD44) in the cell lines was studied by real-time RT-PCR analysis (Figure [1](#F1){ref-type="fig"}, [Supplementary Table S1](#SD1){ref-type="supplementary-material"}).

![Proteoglycan expression in different normal and lymphoid cell lines\
**a.** Quantitative Real-Time RT-PCR. Intensity of the amplified DNA fragments for individual PGs normalized to that of GAPDH. Stacked column compares the contribution of each proteoglycan to the total PGs biosynthetic activity of the cells. **b.** Individual proteoglycans expression in the cell lines. The graph shows the mean expression levels from triplicate experiments (± SD) (OriginPro 8.1).](oncotarget-06-43529-g001){#F1}

The overall expression of a pool of different PG core proteins is presented as composed of the sum of expression levels for all the proteoglycans under study (Figure [1a](#F1){ref-type="fig"}). The main PGs expressed by normal human B cells were CSPGs CD44 and serglycin, whereas EBV-immortalized B cells (LCL) expressed mainly serglycin and the HSPG perlecan. EBV+ BL cells showed moderate expression levels of perlecan only, if any (Figure [1a](#F1){ref-type="fig"}). Immortalization of the cells (LCL) have resulted in significant down-regulation of CD44 and 4--5-fold increase of perlecan expression shifting the overall CSPG:HSPG ratio towards HSPG.

EBV infected LCL and BL cell lines thus showed a different profile of PG expression. Overall transcriptional activity of PG-coding genes in LCL cells was not significantly different although the pattern of PG expression was changed, dominated by the significant down-regulation of CD44 and up-regulation of serglycin and perlecan (Figure [1a, 1b](#F1){ref-type="fig"}). BL cell lines demonstrated impaired potential for PG expression. Perlecan was the dominant PG in EBV+ BL cells independent of the different EBV latency profiles (Figure [1a](#F1){ref-type="fig"}). Interestingly, the Akata cell line was most similar to EBV latency II-III cell lines in this respect.

As to individual PGs, EBV infection correlated to a significant (five to ten times) down-regulation of CD44 expression in EBV+ LCL cells (CBMI-Ral-STO, CBC-JK2-STO, Nad20). Neither EBV (+) nor (−) BL cell lines expressed CD44 regardless of the EBV latency stage (Figure [1a, 1b](#F1){ref-type="fig"}). Serglycin was expressed in normal B cells and LCLs only, whereas none of the BLs expressed this PG at a significant level (Figure [1a, 1b](#F1){ref-type="fig"}). Interestingly, some serglycin protein could still be detected at the protein level in EBV+ latency III BL cell lines (Figure [2a](#F2){ref-type="fig"}). Super-infection of the BL cell line Raji resulted in an increase of serglycin on the cell surface suggesting an involvement of EBV-infection in transcriptional regulation of serglycin (Figure [2b](#F2){ref-type="fig"}).

![Serglycin expression in different normal and lymphoid cell lines\
**a.** Western blot analysis. bc. Serglycin expression at the cell surface of Raji cells upon super-infection with recombinant GFP-coding EBV virus. **b.** EBV infected Raji cells (green - GFP- EBV). **c.** Serglycin expression on GFP-EBV infected Raji cells (red).](oncotarget-06-43529-g002){#F2}

Along with the increased serglycin expression in LCLs, significant up-regulation of perlecan expression was detected (CBMI-Ral-STO, CBC-JK2-STO, Nad20) (Figure [1b](#F1){ref-type="fig"}, [Supplementary Table S1](#SD1){ref-type="supplementary-material"}). This together with increased expression levels of perlecan in BL latency II-III cells and its down-regulation (or disappearance) in the EBV+ latency I BL cells suggest that the perlecan expression could be associated with the EBV latency program of the host cells. In all cell types (B cells, LCL, BL cells) perlecan expression correlated with the adhesive capacity of the cells, which relate to the possible role of the PGs in cell-cell adhesion, however which is also dependent on ICAM-1. The results show that the type of EBV latency program (I or III) is strongly correlated with a certain PG expression profile in LCLs and BL cells.

Different molecular mechanisms drive proteoglycans down-regulation at the different EBV latency stages {#s2_2}
------------------------------------------------------------------------------------------------------

To reveal possible molecular mechanism of PG suppression in the cell lines, we experimentally modulated the EBV latency. It is known that the DNA demethylating agent 5′-deoxyazacytidine (5′-aza-dC) and Trihostatin A (TSA) -- a chromatin structure modulator - are able to activate expression of EBNA2--6 and the LMP genes in latency I cells switching them towards latency II-III \[[@R38], [@R39]\]. To study the possible changes in PGs expression upon this switch, type I cells Rael and Akata as well as LCL cells (CBMI-Ral-STO) and BL latency III cells (Raji) were treated with 5′-aza-dC, TSA or both together and subjected to real-time RT-PCR analysis of the PG expression (Figure [3](#F3){ref-type="fig"}).

![Changes in the expression of different PGs in LCL and BL cells in different latency stages after 5-aza-dC and TSA treatment\
The intensity of the amplified DNA fragments was normalized to that of *GAPDH*. Stacked column shows the added sum of PGs measured.](oncotarget-06-43529-g003){#F3}

No significant changes in PG expression were seen upon aza/TSA treatments in LCLs (CBMI-Ral-STO) or BL of type II-III cells (Raji), although these treatments were capable to increase serglycin expression levels 2,5-fold in LCLs. In contrast to that, type I BLs were very sensitive to the aza/TSA treatment(s) showing activation of different PGs with a dominating up-regulation of perlecan/HSPG2. Different EBV latency I cell lines (Rael and Akata) showed specific sensitivity to the different drugs (5′-aza-dC was more effective in regulation of Rael cells, and TSA was more effective in Akata cells).

The results show that the loss of serglycin expression is a characteristic sign of EBV-positive BLs independently of the latency stages. The overall activation of PG expression upon 5′-aza-dC/TSA treatment in BL latency I but not latency III cells suggests an epigenetic regulation of PG expression. Different molecular mechanisms seem to control the PG down-regulation in EBV+ BL cells in different latency stages.

Transcriptional activity of the HS biosynthetic machinery in normal and lymphoid cells in different EBV latency stages {#s2_3}
----------------------------------------------------------------------------------------------------------------------

Because of the complex protein-polysaccharide nature of proteoglycans, changes could occur both at the protein level (expression of the core proteins of the PGs) or at the polysaccharide (glycosaminoglycan, GAG) level. Biosynthesis and post-synthetic modification of the GAG chains are governed by a complex system of specific enzymes through the un-template mechanism. Their proper expression and ordered activity is of vital importance for the biosynthesis of functionally active PGs.

To analyse the transcriptional activity of heparan sulfate (HS) biosynthetic system, we determined expression levels of the key HS biosynthetic enzyme genes in B-cells, LCLs and BL cells in different latency stages (Table [1](#T1){ref-type="table"}) using real-time RT-PCR analysis (Figure [4](#F4){ref-type="fig"}).

![Expression of the HS biosynthetic system in primary B cells, LCLs and BL cells in different latency stages\
**a.** Quantitative Real-Time PCR. Intensity of the amplified DNA fragments for individual enzymes were normalized to that of *GAPDH*. Stacked column shows a comparison of the contribution of each enzyme to the total transcriptional activity of the HS biosynthetic system in each cell type. **b.** Qualitative structure of the expression of HS biosynthetic system. Expression rates for the individual genes were calculated as percentage of the total transcriptional activity of the system, set to 100%. **c.** Effects of 5′-aza-dC and TSA treatments on HS biosynthetic system transcriptional activity in LCL and BL cells in different latency stages.](oncotarget-06-43529-g004){#F4}

According to the RT-PCR data, overall transcriptional activity of HS-metabolic system was not drastically different between the cell lines (Figure [4a](#F4){ref-type="fig"}). However, differential expression of individual HS biosynthesis-involved genes resulted in cell type-specific transcriptional patterns of HS biosynthetic machinery (Figure [4b](#F4){ref-type="fig"}). LCLs and BL type of II-III cells had similar overall transcriptional patterns and expression levels for these genes, with very high expression of 6OST1/HS6ST1 gene (6-O-sulfotransferase, responsible for the modification of HS polysaccharide chain with sulfate group at 6-position). In contrast, BL type I cells demonstrated moderately impaired overall transcriptional activity of the machinery and specific expression patterns. 6OST1/HS6ST1 expression was significantly inhibited in the cells along with an increased expression of 2OST1/HS2ST1 (2-O-sulfotransferase, which is responsible for the modification of HS polysaccharide chain with sulfate group at 2-position -- a more rare modification).

Interestingly, the 5′-aza-dC/TSA treatment specifically affected the transcriptional activity of HS biosynthesis-genes in BL latency I cells (Rael, Akata) restoring high expression levels of 6OST1/HS6ST1 and shifting their overall transcriptional patterns to that of BL latency II-III cells. This suggests an epigenetic inactivation of the HS biosynthetic system in the BL type I cells (Figure [4c](#F4){ref-type="fig"}). At the same time, no evident effect of the 5′-aza-dC/TSA treatment(s) could be seen in LCL or BL type of II-III cells.

The results show that HS biosynthetic machinery is transcriptionally active in all cell lines under study, although some qualitative differences were detected mainly due to the epigenetic down-regulation of HS biosynthesis-involved genes (especially 6OST1/HS6ST1) in BL latency I cells.

Expression of extracellular matrix components in EBV+ and EBV- lymphoid cells {#s2_4}
-----------------------------------------------------------------------------

A similar approach was used also to study the expression of main components of the extracellular matrix (ECM) (collagen 1A1, fibronectin, elastin) (Figure [5](#F5){ref-type="fig"}).

![Expression of extracellular matrix components in primary B cells, LCLs and BL cells in different latency stages\
**a.** Quantitative Real-Time Q-PCR. Intensity of the amplified DNA fragments normalized to that of *GAPDH*. Bars represent the mean ± SD from triplicate experiments (OriginPro 8.1). **b.** Effects of 5′-aza-dC and TSA treatment on the HS biosynthetic system transcriptional activity in LCL and BL cells in different latency stages.](oncotarget-06-43529-g005){#F5}

According to the RT-PCR data, B-cells expressed collagen 1A1, fibronectin and elastin while LCL and BL cells did so only at a very low level (Figure [5a](#F5){ref-type="fig"}). 5′-aza-dC/TSA treatment(s) was capable to activate these genes only in BL type of I cells but not in BL type of II-III cells suggesting different molecular mechanisms of gene inactivation (Figure [5b](#F5){ref-type="fig"}).

DISCUSSION {#s3}
==========

We show that normal primary B lymphocytes express a broad repertoire of PG core proteins, with CD44 and serglycin as major PGs. Our data are in line with previously published results showing that CD44 \[[@R32]\], serglycin \[[@R9]--[@R11]\] and syndecan-1/CD138 \[[@R15], [@R16]\] are expressed in B lymphocytes. In addition we demonstrate for the first time that B cells express additional proteoglycans (perlecan, glypican-1, CSPG4/NG2, decorin, biglycan, lumican) and a wide variety of PGs is consistently altered in EBV-carrying LCLs compared to primary B lymphocytes.

Interestingly, B cells also express extracellular components like collagen 1A1, fibronectin and elastin. This supports published data that B cells from bone marrow of healthy donors contribute with fibronectin and collagen 1A1 production to the cellular microenvironment \[[@R40]\] and that they are able to activate collagen production by fibroblasts \[[@R41], [@R42]\]. It has been shown that extracellular fibronectin and collagen 1A modulate adhesion of B cells to ECM, which in turn can affect B cell differentiation \[[@R43]\], and contribute to the development of fibrosis and systemic sclerosis \[[@R41], [@R42]\]. Short-term exposure to collagen is sufficient to significantly decrease the survival of DG75 EBV-negative Burkitt lymphoma cells or L428 Hodgkin lymphoma cells via up-regulation of DDR1 \[[@R44]\].

Malignant BL cells showed a pronounced inhibition of PG- and ECM components-genes compared to normal B-cells, with perlecan as the major PG in the cells (Figure [1](#F1){ref-type="fig"}, [5](#F5){ref-type="fig"}). Earlier, lack of CD44-expression in EBV-positive or EBV-negative BL cell lines \[[@R33]\], up-regulation of serglycin and CD44 in EBV+ BL cells \[[@R36]\], down-regulation of syndecan-1/CD138 in EBV-infected multiple myeloma cells \[[@R15]\] and fibronectin and collagen in multiple myeloma patients \[[@R40]\] have already been reported \[[@R33]\].

The low expression levels of PGs and ECM in BL cells correlated with the different EBV latency program \[[@R45]\]. While PG inhibition in BL latency I cells is ensured by epigenetic silencing of the corresponding genes and could be reversed by exposure to 5′-azacytidin and/or Trichostatin A, LCLs and BL latency III cells did not respond to this treatment. These data fit the well-established overall epigenetic profile of these cell lines with epigenetic mechanisms involved in the control of EBV-coding genes (EBNA2--6, LMP1,2) \[[@R46], [@R47]\] as well as hypermethylation of the host cell genome \[[@R48]\] in EBV latency I cells. EBV-associated cancers are characterized by conspicuous hypermethylation of both the viral genome and cellular genes, including tumor suppressor genes \[[@R49], [@R50]\]. LCLs, in contrast, show a pattern of relative hypomethylation of the viral and cellular genomes. It has even been suggested that EBV infection may contribute to tumor development by imposing a "methylator" phenotype \[[@R51], [@R52]\]. Thus, proteoglycans and ECM molecules seem to belong to the large set of genes inactivated by epigenetic mechanism in EBV+ tumor derived cells. Upregulation of PGs and ECM components in B cells by 5-aza-dC and TSA could affect the immune response to these cells *in vivo*.

It is important to note that we focused -- for technical reasons - on the PG core proteins without considering their glycosylation with GAG chains. However, transcriptional activity and expression pattern of HS biosynthesis-involved genes show correlation with the PG core protein expression and is similarly controlled by epigenetic regulation (Table [2](#T2){ref-type="table"}). These data support our hypothesis that a molecular mechanism coordinating the transcriptional activities of the systems to optimize the production of these complex polysaccharide-protein molecules exists \[[@R53]\].

###### Summary of the obtained results

  Cell line         EBV latency   Proteoglycans         HS biosynthetic enzymes     ECM molecules
  ----------------- ------------- --------------------- --------------------------- -----------------------------------
  primary B cells   \-            serglycin, CD44       EXT2, NDST2, 2OST1, 6OST1   fibronectin, collagen1A1, elastin
  CBM1-Ral-STO      III           serglycin, perlecan   NDST2, 6OST1                fibronectin
  CBC-JK2-STO       III           serglycin, perlecan   6OST1                       fibronectin
  Nad20             III           serglycin, perlecan   6OST1                       fibronectin
  Mutu III cl.99    II-III        perlecan              2OST1                       \-
  Raji              II            perlecan              2OST1, 3OST1, 6OST1         \-
  Daudi             II            perlecan              2OST1, 6OST1                \-
  Akata             I             perlecan              2OST1, 6OST1                \-
  Rael              I             \-                    2OST1                       \-
  Mutu I cl.148     I             \-                    2OST1                       \-

The genes with the highest relative expression levels are shown for each cell line. dash--gene(s) are expressed at very low level.

Taken together, our results put focus on the important contribution of proteoglycans in B cell interaction with its microenvironment during differentiation and emphasizes the need to explore further the potential role of PGs and ECM molecules in lymphoma development.

MATERIALS AND METHODS {#s4}
=====================

Cell lines and cell culture {#s4_1}
---------------------------

The CBMI-Ral-STO, CBC-JK2-STO, Nad20, Raji, Daudi, Mutu III cl 99, Rael, Akata, Mutu I cl148 and DG75 human cell lines with different EBV latency stages were obtained from MTC (Karolinska Institute, Sweden). All cell lines were maintained in RPMI medium supplemented with 2 mM L-glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, and 10% fetal bovine serum at 37°C in a humidified 5% CO~2~ incubator. For analysis, cells were harvested by centrifugation at 1000 rpm for 5 min at RT. Cell lines characterization is shown in Table [1](#T1){ref-type="table"}.

5-aza-dC/TSA treatment {#s4_2}
----------------------

Treatment with 5′-deoxyazacytidine (5-aza-dC, 4 μg/ml) or Trichostatin A (TSA, 200 ng/ml) was performed by incubating the cells with the drugs for 72 h or 24 h, respectively. For combined treatment, the cells were incubated with 5-aza-dC (4 μg/ml) for 48 h followed by TSA (200 ng/ml) for an additional 24 h.

Human primary B cell isolation {#s4_3}
------------------------------

B cells were isolated from PBMCs of healthy blood donors (Blood Transfusion Center Solna, Stockholm, Sweden) according \[[@R54]\]. Briefly, B cells were isolated either through negative selection (B Cell Isolation Kit II; Miltenyi Biotec) or by positive selection using biotinylated anti-IgD Ab (Southern Biotech) and Anti-Biotin MicroBeads (Miltenyi Biotec). The purity and B cell composition of each donor were assessed by flow cytometry, staining for CD19-allophycocyanin (HIB19; BD), IgD-FITC (IA6--2; BD), CD38-PECy (HB7; BD), CD27-PE (M-T271; BD), and DAPI (5.7 μM; Sigma-Aldrich) using an LSR II or Fortessa (BD) and analyzed using FlowJo software (TreeStar).

RT-PCR analysis {#s4_4}
---------------

Total RNA was extracted from the cells using the Qiagen RNeasy total RNA purification System (Qiagen) according to the manufacturer\'s instructions. cDNA was synthesized from 1 to 2 μg of total RNA using a First Strand cDNA Synthesis kit (Fermentas, Hanover, MD, USA) and 1/10th of the product was subjected to PCR analysis. Quantitative real-time RT-PCR (qRT-PCR) was performed using the ABI PRISM 7500 Sequence Detector (AppliedBiosystems, USA) and the Maxima SYBR Green/RO master mix (Thermo Scientific) under the following conditions: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. The total reaction volume was 25 μl. *GAPDH* was used as the housekeeping gene. The PCR primers are listed in \[[@R55]\].

Western blotting {#s4_5}
----------------

Cells were lysed with RIPA-buffer containing Protease Inhibitor Cocktail (Sigma), incubated for 30 min on ice, centrifuged for 15 min at 13000g. The protein concentration was quantified using Bradford Bio-Rad Protein Assay (BioRad). Total proteins (15 μg) were treated with NuPAGE LDS Sample Buffer (Life Technologies) containing 10% β-mercaptoethanol for 5 min at 96°C, resolved in 10% SDS-PAGE gels and transferred to nitrocellulose membranes Amersham Protran 0.45 NC (Amersham). The membranes were blocked with 5% milk in PBST (0,1%) for 1 h and incubated with primary antibodies \[mouse anti-serglycin monoclonal (Santa Cruz, 1:200) or mouse anti-β-Actin monoclonal (Santa Cruz), 1:500\] overnight at 4°C followed by secondary goat anti-mouse IgG (H+L)-HRP peroxidase-conjugated antibodies (BioRad) for 2 h at RT. Proteins were detected with an Amersham ECL Western Blotting Detection Reagent (Amersham) according to the manufacturer\'s instructions.

EBV infection of human BL cells {#s4_6}
-------------------------------

EBV-containing conditioned medium was collected from a gastric carcinoma AGS cell line carrying recombinant EBV-GFP (40 h incubation, monolayer). For *in vitro* infection, 10^6^ Raji cells were pelleted by centrifugation at 1000 prm for 5 min at RT, resuspeded in 2 ml virus--containing supernatant with 8 mkg/ml polybrene and incubated on 6-well plate in a humidified incubator at 37°C and 5% CO~2~ for 90 h with shaking every 24 h. For analysis, cells were harvested by centrifugation at 1000 rpm for 5 min at RT.

Immunostaining and FACS analysis {#s4_7}
--------------------------------

Cells were washed with PBS, resuspended in 1ml PBS, 1ml 70% ethanol was added and the cells were incubated for 30 min at 4°C. Then, the cells were washed with PBS, resuspended in mouse anti-serglycin monoclonal primary antibodies in PBS (Santa-Cruz; 1:50) and incubated for 30 min at RT. Staining patterns were visualised with Alexa Fluor^®^ 488-conjugated Goat anti-Mouse IgG (H+L) Secondary Antibodies (Life Technologies, 1:100, 30 min at RT) and analysed using FACSCalibur flow cytometer (BD Biosciences) with CellQuest Pro program.

Statistical analysis {#s4_8}
--------------------

Statistical analyses were performed using a computer program ORIGIN Pro 8.1; *a* value of *p* \< 0.05 was considered as statistically significant. Data are expressed as means ± SEM.
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